Reducing the Dose of Smallpox Vaccine Reduces Vaccine‐Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses

Open Access
Publisher Website
Google Scholar
Abstract
Background. When the decision was made to prepare for a deliberate release of smallpox, the United States had ∼15 million doses of Wyeth Dryvax vaccine, which was known to induce significant morbidity when used undiluted; Sanofi Pasteur, Inc., later identified ∼85 million additional doses in storage. Methods. Eleven vaccine-dose groups, each with 30 vaccinia-naive subjects, were given diluted Dryvax vaccine or 1 of 2 lots of Sanofi Pasteur smallpox vaccine and were evaluated for vaccination success rates, morbidity, and immune responses. Results. Estimated doses of 106.6–C108.2 pfu of virus/mL induced major reactions (or “takes”) in 93%–100% of subjects in each dose group. No differences in vaccination take rates, lesion size, erythema, and induration or in serum neutralizing-antibody response were detected between the groups. However, systemic reactogenicity and missed activities were significantly lower for the vaccine groups given doses of 106.6–C107.2 pfu/mL than for those given doses of 106.6–C108.2 pfu/mL. Conclusions. These findings support the use of a higher dilution of Wyeth Dryvax vaccine and Sanofi Pasteur smallpox vaccine, given that the resulting morbidity should be significantly lower without loss of vaccine effectiveness. A plan for use of higher dilutions would create an enormous stockpile of vaccine.

This publication has 0 references indexed in Scilit: